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History of present illness:  A 65-year-old man presented to the emergency department with a chief complaint 
of progressively worsening oral pain for three days. The patient had previously seen his dentist three days 
prior when the pain began and no lesions or source of pain could be identified. Over the past 24 hours, the 
patient noticed the development of painful lesions in his mouth. He reported decreased intake of solids and 
liquids due to pain. He denied a history of past rashes or any other lesions on his body. 
 
Significant findings: Physical exam findings revealed vesicular lesions on the lip, hard and soft palates which 
did not cross the midline. The lesions appeared in the distribution of the maxillary branch (V2) of the 
trigeminal nerve, consistent with herpes zoster. 
 
Discussion: Herpes zoster, commonly known as shingles, is a frequent reason for patients to present to the 
emergency department or clinic. The prodrome typically involves pain and tingling before the eruption of 
grouped vesicles in a dermatomal distribution and can be accompanied by fever, headache and malaise. It is 
estimated that 30% of Americans will experience at least one episode of herpes zoster in their lifetime. While 
the disease is typically not life-threatening, it can cause significant morbidity.1  
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Herpes zoster is due to reactivation of the varicella zoster virus, which causes chicken pox and remains 
dormant in the dorsal root ganglion. The incidence of the disease increases with age, with the majority of 
cases presenting after the age of 50.2 Risk factors include increasing age, hospitalization, co-morbid 
conditions and cutaneous or mucosal trauma. One study found that those with craniofacial herpes zoster 
were twenty-five times as likely to have had facial trauma in the week prior compared to controls.3 
 
Diagnosis is often clinical, requiring no additional lab tests or imaging. A Tzanck smear may be performed to 
identify multinucleated giant cells. The differential diagnosis for oral lesions includes herpes zoster, primary 
syphilis, aphthous stomatitis and thermal burns.4 Further diagnostic testing, such as direct fluorescent 
antibody testing, polymerase chain reaction (PCR) and viral culture may aid in the diagnosis but are frequently 
not used in the clinical setting. 
 
The treatment of herpes zoster is antiretrovirals and pain control. If the lesions are identified within 72 hours, 
strong evidence exists for the use of acyclovir or one of its derivatives to reduce pain, promote healing, and 
prevent new lesion formation.5 Acyclovir requires more frequent dosing due to poor gastrointestinal 
absorption compared to valacyclovir. Studies have also shown a modest improvement in the resolution of 
symptoms and prevention of post-herpetic neuralgia with the use of valacyclovir.6 Non-steroidal anti-
inflammatories are often adequate for pain control. Early studies found a small benefit with the addition of 
corticosteroids in preventing post-herpetic neuralgia, but a recent meta-analysis found no difference in the 
occurrence of postherpetic neuralgia in patients receiving corticosteroids.7 
 
Transmission is by direct contact with lesions. Patients with oral lesions should be instructed to avoid oral 
contact with others including kissing and sharing of food or beverage. Patients should be expressly advised 
to avoid immunocompromised or pregnant contacts. The virus is no longer transmissible once the lesions are 
crusted over.8 Patients should be instructed to follow up with their primary care provider and dermatology 
if the eruption is severe and to return to the ED if they have any visual changes or spreading of lesions.  
 
The patient was treated with intramuscular ketorolac and given a prescription for valacyclovir. The patient 
was referred to the dermatology clinic but on review of records did not seek follow up care. 
 
Topics: Oral lesions, herpes zoster, shingles. 
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